echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA approves GSK's long-acting HIV drug Cabenuva for teens

    FDA approves GSK's long-acting HIV drug Cabenuva for teens

    • Last Update: 2022-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Recently, ViiV Healthcare, an HIV pharmaceutical company controlled by GlaxoSmithKline, announced that the U.


    The approval of Cabenuva is the first long-acting HIV therapy for adolescents


    Currently, Cabenuva offers co-packages of two injectable drugs: ViiV's cabotevir extended-release injection suspension single-dose vial, and Janssen's rilpivirine extended-release injection suspension single-dose vial


    It is reported that HIV-infected adolescents face greater challenges in daily oral HIV treatment, and face the pressure and difficulty of daily medication


    The FDA approval to expand the treatment population of Cabenuva is based on data from the adult study and the interim analysis at Week 16 of the MOCHA study


    Reference source: ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.